RecruitingPhase 4NCT06312683
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Studying Pouchitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of North Carolina, Chapel Hill
- Principal Investigator
- Edward Barnes, MD, MPHUniversity of North Carolina
- Intervention
- Rifaximin 550 MG Oral Tablet [XIFAXAN](drug)
- Enrollment
- 16 target
- Eligibility
- 18-74 years · All sexes
- Timeline
- 2024 – 2026
Study locations (2)
- NYU IBD Center, New York, New York, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
Collaborators
Bausch Health Americas, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06312683 on ClinicalTrials.govOther trials for Pouchitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07226050CLF065 for Chronic PouchitisCalibr, a division of Scripps Research
- RECRUITINGPHASE4NCT06864403Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the PouchUniversity of North Carolina, Chapel Hill
- RECRUITINGPHASE3NCT06443502A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic PouchitisTakeda
- RECRUITINGEARLY PHASE1NCT05829109Fecal Microbiota Transplant for Patients With Chronic PouchitisMaia Kayal
- ACTIVE NOT RECRUITINGPHASE3NCT03524352the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal AnastomosisNantes University Hospital
- RECRUITINGNCT04912999Inflammatory Bowel Diseases Remission RegistryTel-Aviv Sourasky Medical Center
- RECRUITINGPHASE2NCT03545386Fecal Microbiota Transplantation for PouchitisMcMaster University